VRTX vs IONS Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex Pharmaceuticals is generally evaluated as a highly profitable, franchise-driven biotech with a dominant cystic fibrosis business, while Ionis Pharmaceuticals is assessed as a platform company transitioning from a royalty and partnership model toward building its own independent commercial products. The comparison contrasts an established profit engine against a company still scaling its self-commercialization strategy.
Use this comparison to weigh Vertex's established franchise profitability against Ionis's platform diversification and transition toward independent commercialization.
VRTX holds the edge across 3 of 5 key metrics in this comparison. IONS has delivered stronger 1-year price return (+41.56% vs +39.26%), though VRTX has the better forward P/E setup (24.63x vs -57.23x for IONS). VRTX leads on both revenue growth (12.50%) and operating margin (38.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for IONS (+45.79%) than for VRTX (+3.96%).
- Want exposure to an established, highly profitable biotech franchise
- Value pipeline diversification beyond a single disease area
- Prefer lower binary clinical trial risk than earlier-stage biotechs
- Are comfortable with a premium valuation reflecting franchise quality
- Believe antisense technology has broad, durable therapeutic applicability
- Want exposure to a company transitioning from royalties to independent product sales
- Value a diversified pipeline spanning multiple disease categories
- Are comfortable with commercial ramp execution risk on newer launches
| Metric | VRTX | IONS |
|---|---|---|
| AI score | 49.5 | 37.0 |
| AI rank | #484 | #1418 |
| Latest close | $544.52 | $60.36 |
| 1M return | +14.13% | +16.59% |
| 6M return | +12.03% | -25.62% |
| 1Y return | +39.26% | +41.56% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | IONS |
|---|---|---|
| 1Y ago | $13.58K (+35.8%) started 2025-09-02 | $10.5K (+5.0%) started 2025-09-02 |
| 5Y ago | $27.62K (+176.2%) started 2021-09-01 | $15.18K (+51.8%) started 2021-08-31 |
| 10Y ago | $57.47K (+474.7%) started 2016-09-01 | $20.36K (+103.6%) started 2016-08-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | IONS |
|---|---|---|
| Market cap | $137.3B | $10.03B |
| Trailing P/E | 31.55 | N/A |
| Forward P/E | 24.63 | -57.23 |
| Price/Sales | 10.42 | 11.48 |
| EV/Revenue | 10.44 | 11.71 |
| Analyst target | $563.12 | $88.00 |
| Target upside | +3.96% | +45.79% |
| Metric | VRTX | IONS |
|---|---|---|
| Revenue growth | 12.50% | -40.70% |
| Earnings growth | 8.00% | N/A |
| EPS growth | +8.00% | N/A |
| FCF margin | +20.88% | -39.67% |
| Operating margin | 38.05% | -38.18% |
| Profit margin | 35.00% | -64.66% |
| ROIC proxy | 23.54% | -105.50% |
| Return on equity | 23.54% | -105.50% |
| Dividend yield | N/A | 0.00% |
| Beta | 0.30 | 0.40 |
| Debt/equity | 9.77 | 497.80 |
| Current ratio | 3.19 | 7.89 |
| Quick ratio | 2.54 | 6.85 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | IONS |
|---|---|---|---|
| 1Y | Growth | +35.79% | +4.99% |
| CAGR | +36.04% | +5.02% | |
| Sharpe ratio | 1.06 | 0.23 | |
| Max drawdown | 15.21% | 40.15% | |
| Max daily drop | 4.56% | 23.90% | |
| Max wkly drop | 9.32% | 36.37% | |
| 5Y | Growth | +176.21% | +51.81% |
| CAGR | +22.54% | +8.71% | |
| Sharpe ratio | 0.70 | 0.31 | |
| Max drawdown | 29.07% | 52.36% | |
| Max daily drop | 20.60% | 23.90% | |
| Max wkly drop | 20.71% | 36.37% | |
| 10Y | Growth | +474.69% | +103.58% |
| CAGR | +19.11% | +7.37% | |
| Sharpe ratio | 0.56 | 0.29 | |
| Max drawdown | 41.60% | 70.39% | |
| Max daily drop | 20.70% | 23.90% | |
| Max wkly drop | 22.29% | 36.37% |
| Category | VRTX | IONS |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Ionis Pharmaceuticals, Inc. |
| Sector | Healthcare | Biotechnology |
| Industry | Biotechnology | N/A |
| Core business | Vertex Pharmaceuticals develops and markets therapies for cystic fibrosis and is expanding into pain management, diabetes, and gene-editing treatments through its clinical pipeline. | Ionis Pharmaceuticals develops antisense oligonucleotide therapies targeting a broad range of rare and common diseases, both independently and through partnerships with larger pharmaceutical companies. |
| Investor focus | Investors watch cystic fibrosis franchise durability, commercial uptake of newer non-opioid pain and gene-editing therapies, and pipeline diversification progress. | Investors track the commercial ramp of its independently marketed therapies, partnership milestone and royalty revenue, and pipeline progress across multiple disease areas. |
- Dominant, highly profitable franchise in cystic fibrosis treatments
- Strong balance sheet funding pipeline diversification efforts
- Approved gene-editing and non-opioid pain therapies expanding beyond core franchise
- Proven, validated antisense drug discovery platform with decades of development history
- Growing base of independently commercialized products alongside partner royalties
- Diversified pipeline spanning cardiovascular, neurological, and rare diseases
- Long-term reliance on cystic fibrosis franchise for the bulk of revenue
- New therapy launches carry commercial execution and reimbursement risk
- Patent and competitive dynamics in core disease areas over time
- Newer independently marketed products still building commercial scale
- Reliance on partnership economics for a portion of pipeline value
- Competitive pressure from other RNA-targeted therapeutic modalities
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.